Botox-like wrinkle-reducer shows positive results in trials; investors double down on fertility; few websites transparent about pricing, study finds
GroupM, the media investment arm of WPP, forecasts global ad growth of 4.3% in 2018, and predicts Google and Facebook will strengthen their stranglehold on digital advertising.
Content Collective takes the Pixar film's creators on their own genealogy journeys.
CVS to buy Aetna for $69 billion; J&J buys commercial rights for biotech's experimental hypertension drug; Republicans repeal Obamacare's individual mandate
Publicis Groupe has named Alan Wexler as chief executive of Publicis.Sapient as Chip Register has chosen to retire at the end of the year.
FDA releases information on Exondys 51; Sanofi's dengue vaccine faces new restrictions; Kellyanne Conway named opioid czar
Alex Azar, previously a senior executive at Eli Lilly, proposed granting Part B the authority to negotiate lower prices.
U.K. to be first to sell OTC Viagra; Regeneron offers startup scientific expertise; docs more likely to get poor marks when they reject patient requests
How worried should the industry's other major players be?
Company enlists Patti LaBelle to increase awareness for the pneumococcal pneumonia vaccine
FDA plans new guidance to bring complex generics to market more quickly; BioMarin sells priority review voucher for $125 million; Takeda expects Zika clinical trial results next year
The FDA's Office of Prescription Drug Promotion issued a warning letter to Amherst Pharmaceuticals and Magna Pharmaceutical.
Facebook has formally outlined is advertising policies to its users but the industry feels the internet giant is offloading responsibility instead of stepping up.
Teva to cut thousands of U.S. jobs; Regeneron drops Eylea combo drug development; insurers, drugstores, and hospitals increasingly teaming up
The CEO's experience launching medical reference app Epocrates led him to found a social network for physicians.
WebMD reportedly lays off 10% of workforce; Roche blocks Herceptin biosimilar with patent suit; insurers cover Collegium's Xtampza over Purdue's OxyContin
J&J to hold meeting on maintaining Remicade market share; Acorda ends development of Parkinson's drug; Darzalex notches positive first-line results
Emmy-nominated Maia Samuel becomes executive director of expanded Haymarket Content Lab; Bernadette Casey promoted to executive director of Haymarket Content Hub.
Marketers survey the pluses and minuses of the platform's new 280-character limit.
The FDA approves EpiPen competitor Auvi-Q for small children; pharma executives are warm up to Amazon; Purdue approached states about opioid-epidemic settlement
FDA approves Genentech's hemophilia drug; former Insys CEO pleads not guilty to bribery charges; federal jury rules in favor of Endo in Testim lawsuit
Docs biased against research from poor countries, study finds; Astellas probed over patient-assistance charity support; Acorda reports deaths in Parkinson's trial
Lions Health still stands as a separate two-day event, despite a sweeping revamp of the Cannes Lions festival, disappointing some who decried its lack of full integration within the larger program.
French holding company Publicis has welcomed the raft of changes announced to the Cannes Lions festival Monday, while others have given it a more cautious welcome.
FDA approves AstraZeneca asthma drug; Senate tax reform bill would repeal Obamacare mandate; J&J drops Remicade biosimilar lawsuit
Ketchum, Ogilvy, Porter Novelli, Weber Shandwick, and FleishmanHillard are among the firms that have been awarded past Centers for Medicare and Medicaid Services IDIQ accounts.
Celebrities such as Angela Bassett and Mike Golic share their personal experiences about diabetes.
FDA approves first digital pill; biotech companies race to develop cancer-fighting microbiome drugs; Loxo and Bayer reach $1.55 billion deal for rare cancer drugs
Dynavax receives FDA approval for hepatitis-B vaccine; Novartis strikes R&D deal with gene-editing startup; White House nominates new HHS head
W2O's Windy City office has added three health and analytics leaders over the past six months.
Get America Covered is working to encourage consumers to sign up for coverage through the Affordable Care Act.
AstraZeneca sales fall on generic competition; Anthem broadens access for Duchenne muscular dystrophy drug; researchers are developing new biopsy techniques
GSK hires Google biotech exec to lead R&D; Merck gets FDA-approval for CMV therapy; ex-Lilly exec reportedly top HHS secretary pick
Ty Curran, previously CEO of the sister agencies, will serve as chairman in 2018.
Pharmacy benefit managers are increasingly measuring a patient's outcome in the context of adherence.
FDA to change Risk Evaluation Mitigation Strategies to prevent delayed generic approvals; Ohio rejects drug-price measure; Aetna CEO wants to improve in-person pharmacy experience
A mini wave of state-level rule-making has thrust the issue of restrictions on pharma payments to medical professionals back into the spotlight.
Senator investigates Alkermes' opioid-marketing tactics; FDA approves Roche cancer drugs; CVS to launch next-day delivery nationwide
The CDC has launched the first wave of its awareness campaign about prescription opioids.
Midway through Campaign's audience with Publicis Groupe's Maurice Lévy, a heavily French-accented voice exclaims, "Now it is time for the real boss to arrive."
Valeant sells Addyi back to Sprout; some advertisers halt business with Outcome Health; Amgen cuts R&D jobs
In April, a month or so after brands were accused of funding terrorist videos on YouTube, Procter & Gamble cut down the number of sites its ads ran on by 69%.
The blogger talks the challenges of influencer marketing in healthcare, chronic disease, and big brand activations.
Experimental Gilead and GSK HIV drugs are expected to compete; GSK R&D head resigns; Valeant subsidiary scores eye-drug approval
Teva reports lower-than-expected Q3 earnings; BI and Dicerna partner in NASH drug development; AstraZeneca's experimental asthma drug fails in Phase-III
Forecasts anticipate sales of $1.3 billion in five years.
The divisional VP and head of public affairs has seen it all, including the transformation from a traditional comms organization to a more dynamic and content-led group.
During its third quarter earnings call yesterday, WPP dismissed the threat from management consultants as "overhyped". Analysts concur.
Drug industry spends nearly $50 million to fight drug-price referendum; Novartis weighs sales of generic unit; ICER to evaluate all newly approved drugs
MM&M and PRWeek have revealed the 2017 Health Influencer 50, a list honoring professionals across the health spectrum for their passion, determination, and innovative thinking that has helped guide the industry through two turbulent and exciting decades.
Pfizer Q3 revenue driven by Prevnar sales; President Trump's opioid panel presents draft to combat crisis; Novartis seeks FDA approval for CAR-T therapy Kymriah
Novartis to acquire French biotech in bid to develop new cancer therapies; FDA hires former Mylan exec as comms adviser; health system sees drop in opioid scripts
In 2013, Medicare Part D prescribers who received a gift from a drugmaker prescribed 8% more brand-name drugs.
The HealthiHER project has commissioned a survey of women aged 30 to 60 to inform future campaigns.
Porter Novelli has been appointed to lead a new global CSR brief for pharma and consumer goods giant Johnson & Johnson, as the company faces a major reputation challenge in the US.
CVS Health reportedly in talks to acquire Aetna; Amazon acquires wholesale pharmacy licenses; Merck says June cyberattack disrupted global operations
Optum vet Miller replaces Jessica Boden.
Non-profit challenges Gilead's Sovaldi patent; The Medicines Company to cut hundreds of jobs; Amgen ends R&D for experimental CETP drug
Two years after the first biosimilar approval in the U.S., biosimilars have yet to match sales forecasts. What is their path forward?
FDA develops resources about biosimilars for HCPs; Biogen negotiates royalties for experimental Alzheimer's drug; GSK Q3 sales driven by HIV, respiratory drugs
The agency network is rebranding five subsidiaries under the W2O banner.
Trade group PhRMA's CEO talks about his first year in the job amid public outrage about price gouging.
FDA approves Alexion's Soliris for another rare disease; Sun Pharma debuts companion mobile app for acne drug; Hurricane halts manufacturing in Puerto Rico
The Paris-based pharma company debuted a brand campaign and signature last week.
Biosimilars could save $54 billion in next decade; White House requests drug-pricing task force; FDA approves GSK shingle vaccine
The drugmaker eliminated its U.S. primary care, disease-focused endocrinology, and hospital chronic-care sales teams.
From IKEA to eye-opening health campaigns, S&S Wellness' CCO helps turn emotion into action.
The organization rolled out a video this week as part of its Live Unaddicted campaign to change the perception of addiction treatment.
Merck lays off 1,800 employees, launches new sales force; Celgene ends development of Crohn's disease drug; PBMs come under increased scrutiny
Area 23 netted three gold awards, and 2e Creative won Small Agency of the Year for the third year in a row.
Two point-of-care companies have received hundreds of millions of dollars in funding. One of them, Outcome Health, is facing allegations about padding data.
The FDA approves Kite's CAR-T therapy; Omnicom reports strong Q3 performance for healthcare agencies; Hearst to acquire Rodale, up health presence
More than half of doctors say patients make critical, racist, or sexist comments; Anthem to launch its own PBM; drugmakers face criticism for waste
An FDA advisory committee is scheduled to vote Wednesday on whether to approve Novo's semaglutide, which, if approved, could steal market share from Eli Lilly's Trulicity.
The health startup's system has a foot scanner that can take photos of a patient's feet and can look for potential foot ulcers using a machine learning image classifier.
J&J reports 15% lift in pharma sales in Q3; Apple reportedly considers buying medical clinics; survey finds need for digital investment in payer marketing
Like its consumer-products cousins, pharma marketers are exercising more discipline over online media. Will it yield similar results?
FDA briefing document affirms diabetes drug's efficacy; J&J debuts new tools to improve adherence; AZ says cancer drug data was falsified
Two key creators from Ready Set Rocket share how a thoughtful execution can destigmatize mental illness.
Outcome Health reportedly misled advertisers; FDA committee recommends gene therapy; Avanir drug is highly prescribed by docs paid by company
The association said it is preparing for new FDA approvals for therapies that treat central nervous system and muscular system diseases.
Merck scraps plans for cholesterol drug; oncologist describes how he tells people about his work; researchers question list of side effects in DTC ads
Susan G. Komen and the Breast Cancer Research Foundation are focusing on raising awareness and research money for the deadliest forms of the disease.
Pfizer considers sale of its consumer healthcare business; Express Scripts moves into patient benefit management; China to speed up drug approvals
Patients complain about positive healthcare ads; some drugmakers skirt Open Payment rules; new law requires disclosure of drug price hikes in California
The communications team, led by Jeff Winton, is again researching Astellas' reputation for an updated picture on where the campaign has gotten them so far.
AbbVie to pay $140 million to AndroGel patient; Trump likely to roll back birth-control mandate; patients more likely to respond to expensive drugs
Cigna will no longer cover OxyContin; the AMA no longer supports price-fixing to lower drug prices; Gottlieb is not in favor of 'right-to-try' laws
In the 2015-16 flu season, more than 145 million doses were distributed by manufacturers, according to the Centers for Disease Control and Prevention, but only 41% of American adults received a vaccine.
The FDA approves Mylan's Copaxone generic; 3 out of every 1,000 Americans face $50,000 in drug costs; some ACA premiums may rise by 50%
DKMS worked with Marino on PR for the campaign and with Area 23 on its Comic Con booth.
The FDA wants to improve the generic drug approval process; Allergan CEO responds to criticism of patent deal; breast cancer death rate dropped 40%
The need to simplify access to treatment while finding new ways to keep patients engaged in their health and adherent is an undeniably growing trend.
The FDA tells 75 opioid drugmakers to fund training efforts; epilepsy drug reduces seizure frequency; FDA approves Novo's fast-acting mealtime insulin
Merck to stop developing hep.-C drugs; FDA approves new Lilly breast-cancer drug; California bill would outlaw co-pay cards
Universities stock vending machines with women's health products; AbbVie pays to delay Amgen's Humira biosimilar; more states likely to introduce off-label bills
A leaked email chain shows that WPP intends to withdraw from Ascential's Eurobest awards in London and is in discussions with the organizer about Cannes Lions.
Accenture or CapGemini are more likely to acquire the global agency networks than a Google or Oracle, according to a leading French bank.
AbbVie adds context to CEO's comments on drug pricing; Pandora makes a play for pharma ad dollars; shortages expected of drugs manufactured in Puerto Rico